



**Lybalvi (olanzapine/samidorphan)
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640



Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Lybalvi (olanzapine/samidorphan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____

MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Treatment of schizophrenia in adults <input type="checkbox"/> Treatment of bipolar I disorder in adults <ul style="list-style-type: none"> • as acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate or • as maintenance monotherapy treatment <input type="checkbox"/> Other diagnosis: _____ ICD-10: _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: The prescriber is in consultation with a psychiatrist or a prescriber who specializes in mental health care? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient currently prescribed and using opioids? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient undergoing acute opioid withdrawal? <input type="checkbox"/> Yes <input type="checkbox"/> No Does patient have dementia-related psychosis? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient taking any of the following drugs with clinically relevant interactions : <ul style="list-style-type: none"> • Strong CYP3A4 inducers <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, list medications: _____ • Levodopa and dopamine agonists <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, list medications: _____ Does prescriber attest to patient weight gain and/or metabolic changes that necessitate the use of Lybalvi? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient failed, have a contraindication, or intolerance to a trial of TWO of the following: generic antipsychotics, Latuda, or Vraylar at maximally tolerated dose for at least 4 weeks for each trial? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes please list drugs and dates: _____ If this is a <u>Renewal</u>: Is patient experiencing symptom improvement or maintenance? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient experiencing any treatment-limiting adverse reactions from this medication? <input type="checkbox"/> Yes <input type="checkbox"/> No Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? <hr/> <hr/>		





**Lybalvi (olanzapine/samidorphan)
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640



Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811

